Prostate Cancer Clinical Trial
Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
Summary
This study investigates ways to detect prostate cancer earlier in men who are at increased genetic risk of developing prostate cancer that forms, grows, or spreads quickly (aggressive). Studying samples of blood, urine, and/or tissue in the laboratory may help doctors further understand the genetics of prostate cancer and help identify ways to detect cancer earlier, thereby improving treatment and methods of early detection in the future.
Full Description
OUTLINE:
Participants undergo collection of blood, urine, and/or tissue samples every 6-12 months, when any biopsy occurs, and if relevant, at time of curative therapy and 3-9 months after completion of curative therapy for up to 3 years.
Eligibility Criteria
Inclusion Criteria:
People with prostates ≥40 years of age
Documented germline pathogenic variant in known or suspected genes associated with prostate cancer risk.
Exclusion Criteria:
Prior diagnosis of prostate cancer
Medical contraindication to any of the study procedures (e.g., prostate biopsy)
For all cancer types except non-melanoma skin cancer, any cancer treatment with curative intent within the past 12 months (e.g., surgery, radiation, chemotherapy, immunotherapy)
Unable to provide written informed consent
Unable or unwilling to complete clinical care and study procedures as indicated by the study protocol.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 4 Locations for this study
Portland Oregon, 97239, United States More Info
Principal Investigator
Philadelphia Pennsylvania, 19104, United States More Info
Principal Investigator
San Antonio Texas, 78229, United States More Info
Principal Investigator
Seattle Washington, 98109, United States More Info
Principal Investigator
How clear is this clinincal trial information?